Hospitalization for adverse events under abiraterone or enzalutamide exposure in real‐world setting: A French population‐based study on prostate cancer patients-Reference-Cited by-同舟云学术

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real‐world setting: A French population‐based study on prostate cancer patients

Published:2021-07-22 Issue:1 Volume:88 Page:336-346
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Scailteux Lucie‐Marie¹²³^ORCID,Despas Fabien⁴⁵,Balusson Frédéric²,Campillo‐Gimenez Boris⁶⁷,Mathieu Romain⁸⁹,Vincendeau Sébastien⁸,Happe André²³,Nowak Emmanuel³¹⁰,Kerbrat Sandrine²³,Oger Emmanuel¹²³^ORCID

Affiliation:

1. Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Department of Clinical Pharmacology Rennes University Hospital Rennes France

2. EA 7449 REPERES ‘Pharmacoepidemiology and Health Services Research’ Univ Rennes Rennes France

3. PEPS research consortium Rennes France

4. Department of Clinical Pharmacology Toulouse University Hospital Toulouse France

5. INSERM CIC 1436 Toulouse, Centre d'Investigation Clinique de Toulouse Centre Hospitalier Universitaire de Toulouse France

6. Eugène Marquis Comprehensive Cancer Regional Center Rennes France

7. INSERM 1099 ‘LTSI’ Univ Rennes Rennes France

8. Urology Department Rennes University Hospital Rennes France

9. CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) ‐ UMR_S 1085 Univ Rennes Rennes France

10. Université de Bretagne Loire, Université de Brest, INSERM CIC 1412, CHRU de Brest France

Funder

National Health Insurance Administration

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14972

Reference56 articles.

1. Treatment of Advanced Prostate Cancer

2. https://www.ema.europa.eu/en/documents/variation-report/zytiga-h-c-2321-ii-0047-epar-assessment-report-variation_en.pdf. Accessed July 22 2020.

3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies

4. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer

5. https://www.ema.europa.eu/en/documents/product-information/zytiga-epar-product-information_en.pdf. Accessed July 27 2020.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16

2. Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System;ESMO Real World Data and Digital Oncology;2024-06

3. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide;Acta Oncologica;2024-04-09

4. Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review;Future Oncology;2023-11

5. Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide;Clinical Genitourinary Cancer;2023-10